@ttppxxYou called me a liar and then can't show me where i haven't told the truth.
Then true to form you post half a quote from me which completely changes it's context.
Always twisting the conversation because you have no valid content to add.
You can keep posting your vapid low content sycophantic rants and get some thumbs up if that's what floats your boat.
Ill sum up the risks as i see it without using any sciencey words so you can grasp it;
Imaging
A superior image from Cu64 and better at detection of small lesions than the others on the older scanners but in 2+ years when clarity has theirs in the market the nee scanners will be ubiquitous in high volume settings.
Theres already pressure on scanning slots and they'll do it in one quarter of the time and yield the same result as Clarity's with any agent.
This likely makes large pharma see more risk with such an investment looking ahead 10+ years.
Prostate cancer therapy
PSA response and complete response is not a good predictor of overall survival.
Pluvicto has a complete response rate of 21% and an OS of 15 months.
TLX591 and perhaps TLX592 will likely provide the highest overall survival benefit as has already been shown in a trial although Cu6 will almost definitely outdo Pluvicto.
Take from that what you will.
I bailed on the last little bit of my holding at $6.02 today.
Looking like it might dip into the $4s?
(20min delay)